FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096840197> ?p ?o ?g. }

• W2096840197 endingPage "412" @default.
• W2096840197 startingPage "404" @default.
• W2096840197 abstract "The aim of this study was to compare the efficacy and tolerability of the new aromatase inhibitor 'ARIMIDEX' (anastrozole) with megestrol acetate in the treatment of advanced breast cancer in postmenopausal women. Anastrozole is a new potent and highly selective non-steroidal aromatase inhibitor. We conducted a prospective randomised trial comparing two doses of anastrozole (1 and 10 mg orally once daily) with megestrol acetate (40 mg orally four times daily) in postmenopausal patients with advanced breast cancer who progressed after prior tamoxifen therapy. All patients were analysed for efficacy as randomised (intention to treat) and for tolerability as per treatment received. Of the 378 patients who entered the study, 135 were randomised to anastrozole 1 mg, 118 to anastrozole 10 mg, and 125 patients to megestrol acetate. After a median follow-up of 192 days, response rate which included complete response, partial response and patients who had disease stabilisation for 6 months or more was 34% for anastrozole 1 mg, 33.9% for anastrozole 10 mg and 32.8% for megestrol acetate. There were no statistically significant differences between either dose of anastrozole and megestrol acetate in terms of objective response rate, time to objective progression of disease or time to treatment failure. The three treatments were generally well tolerated, but more patients on megestrol acetate reported weight gain, oedema and dyspnoea as adverse events while more patients on anastrozole reported gastro-intestinal disorders, usually in the form of mild transient nausea. Patients on anastrozole did not report higher incidences of oestrogen withdrawal symptoms. Anastrozole is an effective and well tolerated treatment for postmenopausal patients with advanced breast cancer. The higher 10 mg dose did not result in additional clinical benefit, but was well tolerated reflecting the good therapeutic margin with anastrozole. Based on this data, anastrozole 1 mg should be the recommended therapeutic dose." @default.
• W2096840197 created "2016-06-24" @default.
• W2096840197 creator A5002412211 @default.
• W2096840197 creator A5008103307 @default.
• W2096840197 creator A5015900909 @default.
• W2096840197 creator A5019219859 @default.
• W2096840197 creator A5052648400 @default.
• W2096840197 creator A5055712143 @default.
• W2096840197 creator A5058219705 @default.
• W2096840197 creator A5058301627 @default.
• W2096840197 creator A5062149739 @default.
• W2096840197 creator A5076155394 @default.
• W2096840197 creator A5084436263 @default.
• W2096840197 date "1996-03-01" @default.
• W2096840197 modified "2023-10-01" @default.
• W2096840197 title "A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *" @default.
• W2096840197 cites W1792161227 @default.
• W2096840197 cites W1884665868 @default.
• W2096840197 cites W1933022110 @default.
• W2096840197 cites W1970325604 @default.
• W2096840197 cites W1973632800 @default.
• W2096840197 cites W1974523663 @default.
• W2096840197 cites W1977057354 @default.
• W2096840197 cites W1983235754 @default.
• W2096840197 cites W1995876524 @default.
• W2096840197 cites W2002905683 @default.
• W2096840197 cites W2014328262 @default.
• W2096840197 cites W2016317511 @default.
• W2096840197 cites W2018667612 @default.
• W2096840197 cites W2046985419 @default.
• W2096840197 cites W2047502119 @default.
• W2096840197 cites W2054702701 @default.
• W2096840197 cites W2058306712 @default.
• W2096840197 cites W2072761575 @default.
• W2096840197 cites W2080770259 @default.
• W2096840197 cites W2085103189 @default.
• W2096840197 cites W2093729267 @default.
• W2096840197 cites W2114712559 @default.
• W2096840197 cites W2134488331 @default.
• W2096840197 cites W2138839431 @default.
• W2096840197 cites W2157681187 @default.
• W2096840197 cites W2225973205 @default.
• W2096840197 cites W2228157008 @default.
• W2096840197 cites W2261484698 @default.
• W2096840197 cites W2264660216 @default.
• W2096840197 cites W2312623985 @default.
• W2096840197 cites W2965577516 @default.
• W2096840197 doi "https://doi.org/10.1016/0959-8049(95)00014-3" @default.
• W2096840197 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8814682" @default.
• W2096840197 hasPublicationYear "1996" @default.
• W2096840197 type Work @default.
• W2096840197 sameAs 2096840197 @default.
• W2096840197 citedByCount "244" @default.
• W2096840197 countsByYear W20968401972012 @default.
• W2096840197 countsByYear W20968401972013 @default.
• W2096840197 countsByYear W20968401972014 @default.
• W2096840197 countsByYear W20968401972015 @default.
• W2096840197 countsByYear W20968401972016 @default.
• W2096840197 countsByYear W20968401972017 @default.
• W2096840197 countsByYear W20968401972018 @default.
• W2096840197 countsByYear W20968401972020 @default.
• W2096840197 countsByYear W20968401972021 @default.
• W2096840197 countsByYear W20968401972023 @default.
• W2096840197 crossrefType "journal-article" @default.
• W2096840197 hasAuthorship W2096840197A5002412211 @default.
• W2096840197 hasAuthorship W2096840197A5008103307 @default.
• W2096840197 hasAuthorship W2096840197A5015900909 @default.
• W2096840197 hasAuthorship W2096840197A5019219859 @default.
• W2096840197 hasAuthorship W2096840197A5052648400 @default.
• W2096840197 hasAuthorship W2096840197A5055712143 @default.
• W2096840197 hasAuthorship W2096840197A5058219705 @default.
• W2096840197 hasAuthorship W2096840197A5058301627 @default.
• W2096840197 hasAuthorship W2096840197A5062149739 @default.
• W2096840197 hasAuthorship W2096840197A5076155394 @default.
• W2096840197 hasAuthorship W2096840197A5084436263 @default.
• W2096840197 hasConcept C121608353 @default.
• W2096840197 hasConcept C126322002 @default.
• W2096840197 hasConcept C143998085 @default.
• W2096840197 hasConcept C197934379 @default.
• W2096840197 hasConcept C2776215463 @default.
• W2096840197 hasConcept C2777176818 @default.
• W2096840197 hasConcept C2778375690 @default.
• W2096840197 hasConcept C2778504769 @default.
• W2096840197 hasConcept C2779320873 @default.
• W2096840197 hasConcept C2780580376 @default.
• W2096840197 hasConcept C2780723184 @default.
• W2096840197 hasConcept C530470458 @default.
• W2096840197 hasConcept C71924100 @default.
• W2096840197 hasConceptScore W2096840197C121608353 @default.
• W2096840197 hasConceptScore W2096840197C126322002 @default.
• W2096840197 hasConceptScore W2096840197C143998085 @default.
• W2096840197 hasConceptScore W2096840197C197934379 @default.
• W2096840197 hasConceptScore W2096840197C2776215463 @default.
• W2096840197 hasConceptScore W2096840197C2777176818 @default.
• W2096840197 hasConceptScore W2096840197C2778375690 @default.
• W2096840197 hasConceptScore W2096840197C2778504769 @default.
• W2096840197 hasConceptScore W2096840197C2779320873 @default.
• W2096840197 hasConceptScore W2096840197C2780580376 @default.

• next